Jyoti Mayadev, MD

University of California, San Diego Medical Center

San Diego, CA

Disclosures:

Presentations

Sep 30

343 - Phase 3 Study of Pembrolizumab (Pembro) + Adjuvant Chemotherapy (CT) ± Radiotherapy (RT) for Newly Diagnosed, High-Risk Endometrial Cancer (EC): Exploratory Analysis of Disease-Specific-Free Survival

04:20pm - 04:30pm PT